

Brian Calingaert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1522251/publications.pdf>

Version: 2024-02-01

71
papers

3,686
citations

126907

33
h-index

128289

60
g-index

73
all docs

73
docs citations

73
times ranked

4597
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 435-446.	2.4	0
2	The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the <scp>United States</scp> medicare database. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	4
3	Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). <i>Clinical Epidemiology</i> , 2021, Volume 13, 1141-1153.	3.0	13
4	Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures. <i>Pharmaceutical Medicine</i> , 2019, 33, 235-246.	1.9	3
5	Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures. <i>Pharmaceutical Medicine</i> , 2019, 33, 219-233.	1.9	6
6	Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States. <i>Prostate Cancer</i> , 2019, 2019, 1-7.	0.6	8
7	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 572-577.	2.1	12
8	Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive Bladder. <i>Epidemiology</i> , 2019, 30, e8-e9.	2.7	0
9	Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. <i>Epidemiology</i> , 2018, 29, 308-313.	2.7	51
10	Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. <i>Epidemiology</i> , 2018, 29, e41-e42.	2.7	15
11	Epidemiology of Adult Soft-Tissue Sarcomas in Germany. <i>Sarcoma</i> , 2018, 2018, 1-11.	1.3	24
12	A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation –) Tj ETQq0 0 0.0 BT /Overlock 10 T		
13	Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 953-961.	1.9	2
14	Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. <i>Drugs - Real World Outcomes</i> , 2018, 5, 109-116.	1.6	2
15	Proportions of cancer cases in primary care, hospital, and cancer registry data among patients treated for overactive bladder. <i>Epidemiology</i> , 2018, , 1.	2.7	0
16	Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 615-624.	1.9	14
17	The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 446-458.	1.9	1
18	Incidence of second primary malignancies (SPM) in men with castration-resistant prostate cancer (CRPC) in SEER-Medicare database.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13080-e13080.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Cardiovascular risk associated with the use of glitazones, metformin and sulfonyleureas: meta-analysis of published observational studies. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 14.	1.7	28
20	Topiramate use during pregnancy and major congenital malformations in multiple populations. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2015, 103, 269-275.	1.6	21
21	Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. <i>Journal of Gastric Cancer</i> , 2015, 15, 87.	2.5	23
22	Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users. <i>Current Drug Safety</i> , 2014, 9, 23-28.	0.6	12
23	The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 129.	1.7	62
24	Topiramate use in pregnancy and the birth prevalence of oral clefts. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1017-1025.	1.9	65
25	Risk of Acute Liver Injury Associated with the Use of Moxifloxacin and Other Oral Antimicrobials: A Retrospective, Population-Based Cohort Study. <i>Pharmacotherapy</i> , 2014, 34, 336-349.	2.6	23
26	Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 559-570.	1.9	117
27	Individual NSAIDs and Upper Gastrointestinal Complications. <i>Drug Safety</i> , 2012, 35, 1127-1146.	3.2	308
28	Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 810-817.	1.9	58
29	Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. <i>Influenza and Other Respiratory Viruses</i> , 2012, 6, 44-51.	3.4	23
30	Individual NSAIDs and Upper Gastrointestinal Complications. <i>Drug Safety</i> , 2012, 35, 1127-1146.	3.2	139
31	Patient Factors Associated with Glucagonlike Peptide 1 Receptor Agonist use with and without Insulin. <i>Endocrine Practice</i> , 2011, 17, 707-716.	2.1	9
32	Folic acid supplementation before and during pregnancy in the Newborn Epigenetics Study (NEST). <i>BMC Public Health</i> , 2011, 11, 46.	2.9	110
33	Stroke risk and NSAIDs: a systematic review of observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1225-1236.	1.9	83
34	Use of Long-Acting β_2 -Agonists and Inhaled Steroids in Asthma: Meta-analysis of Observational Studies. <i>Journal of Asthma</i> , 2010, 47, 439-446.	1.7	24
35	Single Nucleotide Polymorphisms in the <i>TP53</i> Region and Susceptibility to Invasive Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 2349-2357.	0.9	63
36	Relationship between tamoxifen use and high risk endometrial cancer histologic types. <i>Gynecologic Oncology</i> , 2009, 112, 150-154.	1.4	61

#	ARTICLE	IF	CITATIONS
37	The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. <i>Gynecologic Oncology</i> , 2009, 112, 511-516.	1.4	57
38	Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. <i>Community Oncology</i> , 2009, 6, 70-77.	0.2	4
39	Attitudes Regarding the Use of Hematopoietic Colony-Stimulating Factors and Maintenance of Relative Dose Intensity Among Gynecologic Oncologists. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 447-454.	2.5	4
40	Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. <i>Clinical Immunology</i> , 2008, 126, 345-352.	3.2	89
41	Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women. <i>American Journal of Epidemiology</i> , 2008, 167, 1059-1069.	3.4	99
42	Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 585-593.	2.5	34
43	Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1841.2-1842.	2.5	0
44	Polymorphism in the <i>IL18</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3567-3572.	2.5	18
45	Trinucleotide Repeat Polymorphisms in the Androgen Receptor Gene and Risk of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 473-480.	2.5	51
46	The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 104, 401-405.	1.4	75
47	Outcomes in surgical stage I uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2007, 105, 677-682.	1.4	99
48	The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 107, 285-291.	1.4	128
49	Pelvic Lymph Node Count is an Important Prognostic Variable for FIGO Stage I and II Endometrial Carcinoma With High-Risk Histology. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, 642-644.	0.4	0
50	Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. <i>Gynecologic Oncology</i> , 2006, 102, 92-97.	1.4	187
51	Analgesic Drug Use and Risk of Ovarian Cancer. <i>Epidemiology</i> , 2006, 17, 104-107.	2.7	68
52	Antidepressant Medication Use for and Risk of Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2005, 105, 725-730.	2.4	18
53	Menopausal hormones and risk of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 76-82.	1.3	30
54	Transforming growth factor β 2 receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. <i>Gynecologic Oncology</i> , 2005, 97, 543-549.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 99, 689-695.	1.4	99
56	Anthropometric Measurements and Epithelial Ovarian Cancer Risk in African-American and White women. <i>Cancer Causes and Control</i> , 2005, 16, 955-963.	1.8	41
57	Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3668-3675.	1.6	406
58	Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. <i>Gynecologic Oncology</i> , 2004, 93, 429-434.	1.4	57
59	PROSPECTIVE AND LONGITUDINAL PATIENT SELF-ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE FOLLOWING RADICAL PERINEAL PROSTATECTOMY. <i>Journal of Urology</i> , 2004, 172, 264-268.	0.4	31
60	144: A Prospective Longitudinal Study of Quality of Life Following Radical Perineal Prostatectomy. <i>Journal of Urology</i> , 2004, 171, 38-38.	0.4	0
61	Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. <i>Gynecologic Oncology</i> , 2003, 90, 75-82.	1.4	68
62	Matrix Metalloproteinase-1 Gene Promoter Polymorphism and Risk of Ovarian Cancer. <i>Journal of the Society for Gynecologic Investigation</i> , 2003, 10, 381-387.	1.7	11
63	Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4396-403.	7.0	39
64	Pre-Counseling Education Materials for BRCA Testing: Does Tailoring Make a Difference?. <i>Genetic Testing and Molecular Biomarkers</i> , 2002, 6, 93-105.	1.7	68
65	Impact of Progestin and Estrogen Potency in Oral Contraceptives on Ovarian Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2002, 94, 32-38.	6.3	152
66	Tag Reporting Rate Estimation: 2. Use of High-Reward Tagging and Observers in Multiple-Component Fisheries. <i>North American Journal of Fisheries Management</i> , 2002, 22, 727-736.	1.0	36
67	Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). <i>Cancer Causes and Control</i> , 2002, 13, 807-811.	1.8	50
68	Tag Reporting Rate Estimation: 2. Use of High-Reward Tagging and Observers in Multiple-Component Fisheries. , 2002, 22, 727.		2
69	Types and Duration of Symptoms Prior to Diagnosis of Invasive or Borderline Ovarian Tumor. <i>Gynecologic Oncology</i> , 2001, 83, 466-471.	1.4	52
70	Tag Reporting Rate Estimation: 1. An Evaluation of the High-Reward Tagging Method. <i>North American Journal of Fisheries Management</i> , 2001, 21, 521-532.	1.0	125
71	Tag Reporting Rate Estimation: 1. An Evaluation of the High-Reward Tagging Method. , 2001, 21, 521.		2